SFM
FOLD

Soros Fund Management’s Amicus Therapeutics FOLD Stock Holding History

Soros Fund Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.2M Buy
5,753,186
+753,186
+15% +$10.8M 0.91% 26
2025
Q4 		$71.2M Buy
+5,000,000
New +$49.1M 0.82% 42
2014
Q3 		– Sell
-70,500
Closed -$235K – 288
2014
Q2 		$235K Buy
+70,500
New +$165K ﹤0.01% 293

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Soros Fund Management's FOLD Position: Q1 2026 in Review

Soros Fund Management increased its Amicus Therapeutics (FOLD) stake by 15% in Q1 2026, buying an estimated $10.8M and bringing the position to 5,753,186 shares worth $83.2M. The position accounts for 0.91% of the portfolio, ranked #26.

Soros Fund Management first reported a position in FOLD in Q2 2014 and has held it in 3 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Soros Fund Management held 5,753,186 shares of Amicus Therapeutics worth $83.2M as of Q1 2026.
  • Soros Fund Management bought 753,186 Amicus Therapeutics shares in Q1 2026, an estimated $10.8M.
  • Amicus Therapeutics made up 0.91% of Soros Fund Management's portfolio in Q1 2026, its #26 holding.
  • Soros Fund Management first reported a position in Amicus Therapeutics in Q2 2014 and has held it in 3 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Soros Fund Management's 13F filing for Q1 2026, filed 15 May 2026.